

Contents

List of Contributors	XI
Preface	XV
A Personal Foreword	XVII

Part One Hit Finding and Profiling for Protein Kinases: Assay Development and Screening, Libraries 1

1	<i>In Vitro</i> Characterization of Small-Molecule Kinase Inhibitors	3
	<i>Doris Hafenbradl, Matthias Baumann, and Lars Neumann</i>	
1.1	Introduction	3
1.2	Optimization of a Biochemical Kinase Assay	4
1.2.1	Step 1: Identification of a Substrate and Controlling of the Linearity between Signal and Kinase Concentration	4
1.2.2	Step 2: Assay Wall and Optimization of the Reaction Buffer	6
1.2.3	Step 3: The Michaelis–Menten Constant K_m and the ATP Concentration	10
1.2.4	Step 4: Signal Linearity throughout the Reaction Time and Dependence on the Kinase Concentration	12
1.2.5	Step 5: Assay Validation by Measurement of the IC_{50} of Reference Inhibitors	15
1.3	Measuring the Binding Affinity and Residence Time of Unusual Kinase Inhibitors	15
1.3.1	Washout Experiments	18
1.3.2	Surface Plasmon Resonance	19
1.3.3	Classical Methods with Fluorescent Probes	21
1.3.4	Preincubation of Target and Inhibitor	22
1.3.5	Reporter Displacement Assay	22
1.3.6	Implications for Drug Discovery	25
1.4	Addressing ADME Issues of Protein Kinase Inhibitors in Early Drug Discovery	26

1.4.1	Introduction	26
1.4.2	Experimental Approaches to Drug Absorption	30
1.4.2.1	Measuring Solubility	30
1.4.2.2	Measuring Lipophilicity and Ionization	30
1.4.2.3	Measuring Permeability	31
1.4.2.4	Transporter Assays Addressing P-gp Interaction	33
1.4.3	Experimental Approaches to Drug Metabolism	34
1.4.3.1	Background and Concepts	34
1.4.3.2	Measuring Metabolic Stability	37
1.4.3.3	Measuring CYP450 Inhibition	39
	References	39
2	Screening for Kinase Inhibitors: From Biochemical to Cellular Assays	45
	<i>Jan Eickhoff and Axel Choidas</i>	
2.1	Introduction	45
2.1.1	Kinase Inhibitors for Dissection of Signaling Pathways	46
2.1.2	Cellular Kinase Assays for Drug Discovery Applications	46
2.2	Factors that Influence Cellular Efficacy of Kinase Inhibitors	47
2.2.1	Competition from ATP	47
2.2.2	Substrate Phosphorylation Levels	51
2.2.3	Ultrasensitivity of Kinase Signaling Cascades	51
2.2.4	Cell Permeability	52
2.2.5	Cellular Kinase Concentrations	53
2.2.6	Effects of Inhibitors Not Related to Substrate Phosphorylation	54
2.3	Assays for Measurement of Cellular Kinase Activity	55
2.3.1	Antibody-Based Detection	56
2.3.2	High-Content Screening	59
2.3.3	Use of Genetically Engineered Cell Lines	60
2.3.4	Genetically Encoded Biosensors	61
2.3.5	Label-Free Technologies	62
2.3.6	Analysis of Kinase Family Selectivity	62
2.3.7	SILAC	62
2.3.8	Affinity Chromatography with Immobilized Kinase Inhibitors	63
2.4	Outlook	63
	References	64
3	Dissecting Phosphorylation Networks: The Use of Analogue-Sensitive Kinases and More Specific Kinase Inhibitors as Tools	69
	<i>Matthias Rabiller, Jeffrey R. Simard and Daniel Rauh</i>	
3.1	Introduction	69
3.2	Chemical Genetics	71
3.2.1	Engineering ASKA Ligand–Kinase Pairs	71
3.3	The Application of ASKA Technology in Molecular Biology	76
3.3.1	Identification of Kinase Substrates	76

- 3.3.2 Studies on Kinase Inhibition 76
- 3.3.3 Alternative Approaches to Specifically Targeting Kinases of Interest 78
- 3.4 Conclusions and Outlook 80
- References 81

Part Two Medicinal Chemistry 85

4 Rational Drug Design of Kinase Inhibitors for Signal Transduction Therapy 87

György Kéri, László Órfi, and Gábor Németh

- 4.1 The Concept of Rational Drug Design 88
- 4.2 3D Structure-Based Drug Design 89
- 4.3 Ligand-Based Drug Design 92
 - 4.3.1 Active Analogue Approach 92
 - 4.3.2 3D Quantitative Structure–Activity Relationships 92
- 4.4 Target Selection and Validation 93
- 4.5 Personalized Therapy with Kinase Inhibitors 96
 - 4.5.1 Target Fishing: Kinase Inhibitor-Based Affinity Chromatography 97
- 4.6 The NCL™ Technology and Extended Pharmacophore Modeling (Prediction-Oriented QSAR) 99
- 4.7 Non-ATP Binding Site-Directed or Allosteric Kinase Inhibitors 101
- 4.8 The Master Keys for Multiple Target Kinase Inhibitors 102
 - 4.8.1 Application of *KinaTör*™ for the Second-Generation Kinase Inhibitors 105
- 4.9 Conclusions 107
- References 109

5 Kinase Inhibitors in Signal Transduction Therapy 115

György Kéri, László Órfi, and Gábor Németh

- 5.1 VEGFR (Vascular Endothelial Growth Factor Receptor) 115
- 5.2 Flt3 (FMS-Like Tyrosine Kinase 3) 116
- 5.3 Bcr-Abl (Breakpoint Cluster Region–Abelson Murine Leukemia Viral Oncogene Homologue) 118
- 5.4 EGFR (Epidermal Growth Factor Receptor) 118
- 5.5 IGFR (Insulin-Like Growth Factor Receptor) 120
- 5.6 FGFR (Fibroblast Growth Factor Receptor) 120
- 5.7 PDGFR (Platelet-Derived Growth Factor Receptor) 121
- 5.8 c-Kit 121
- 5.9 Met (Mesenchymal-Epithelial Transition Factor) 122
- 5.10 Src 123
- 5.11 p38 MAPKs (Mitogen-Activated Protein Kinases) 123
 - 5.12 ERK1/2 124
 - 5.13 JNK (c-Jun N-Terminal Kinase, MAPK8) 126
 - 5.14 PKC (Protein Kinase C) 126
 - 5.15 CDKs (Cyclin-Dependent Kinases) 127

5.16	Auroras	127
5.17	Akt/PKB (Protein Kinase B)	129
5.18	Phosphoinositide 3-Kinases	129
5.19	Syk (Spleen Tyrosine Kinase)	130
5.20	JAK (Janus Kinase)	130
5.21	Kinase Inhibitors in Inflammation and Infectious Diseases	131
5.21.1	Inflammation	131
5.21.2	Infection	132
	References	134

6 Design Principles of Deep Pocket-Targeting Protein Kinase Inhibitors 145

Alexander C. Backes, Gerhard Müller, and Peter C. Sennhenn

6.1	Introduction	145
6.2	Classification of Protein Kinase Inhibitors	147
6.3	Type II Inhibitors	150
6.4	Common Features of Type II Inhibitors	154
6.5	Design Strategies for Type II Inhibitors	155
6.5.1	F2B Approach	160
6.5.2	B2F Approach	166
6.5.3	B2B Approach	169
6.5.4	Hybrid (F2B + B2F) Approach	173
6.6	Comparative Analysis of the Different Design Strategies	180
6.7	Conclusions and Outlook	187
	References	190

7 From Discovery to Clinic: Aurora Kinase Inhibitors as Novel Treatments for Cancer 195

Nicola Heron

7.1	Introduction	195
7.2	Biological Roles of the Aurora Kinases	195
7.3	Aurora Kinases and Cancer	196
7.4	<i>In Vitro</i> Phenotype of Aurora Kinase Inhibitors	197
7.5	Aurora Kinase Inhibitors	203
7.5.1	The Discovery of AZD1152	203
7.5.1.1	Anilinoquinazolines: ZM447439	203
7.5.1.2	Next-Generation Quinazolines: Heterocyclic Analogues	204
7.5.1.3	Amino-Thiazolo and Pyrazolo Acetanilide Quinazolines	208
7.5.2	MK-0457 (VX-680)	214
7.5.3	PHA-739358	215
7.5.4	MLN8054	219
7.5.5	AT9283	220
7.6	X-Ray Crystal Structures of Aurora Kinases	221
7.7	Summary	221
	References	222

Part Three Application of Kinase Inhibitors to Therapeutic Indication Areas 229

- 8 Discovery and Design of Protein Kinase Inhibitors: Targeting the Cell cycle in Oncology 231**
Mokdad Mezna, George Kontopidis, and Campbell McInnes
- 8.1 Protein Kinase Inhibitors in Anticancer Drug Development 231
- 8.2 Structure-Guided Design of Small-Molecule Inhibitors of the Cyclin-Dependent Kinases 233
- 8.3 Catalytic Site Inhibitors 234
- 8.4 ATP Site Specificity 236
- 8.5 Alternate Strategies for Inhibiting CDKs 239
- 8.6 Cyclin Groove Inhibitors (CGI) 240
- 8.7 Inhibition of CDK–Cyclin Association 242
- 8.8 Recent Developments in the Discovery and the Development of Aurora Kinase Inhibitors 242
- 8.9 Development of Aurora Kinase Inhibitors through Screening and Structure-Guided Design 244
- 8.10 Aurora Kinase Inhibitors in Clinical Trials 248
- 8.11 Progress in the Identification of Potent and Selective Polo-Like Kinase Inhibitors 250
- 8.12 Development of Small-Molecule Inhibitors of PLK1 Kinase Activity 252
- 8.13 Discovery of Benzthiazole PLK1 Inhibitors 254
- 8.14 Recent Structural Studies of the Plk1 Kinase Domain 255
- 8.15 Additional Small-Molecule PLK1 Inhibitors Reported 256
- 8.16 The Polo-Box Domain 257
- 8.17 Future Developments 259
- References 259
- 9 Medicinal Chemistry Approaches for the Inhibition of the p38 MAPK Pathway 271**
Stefan Laufer L, Simona Margutti, Dowinik Hauser
- 9.1 Introduction 271
- 9.2 p38 MAP Kinase Basics 271
- 9.3 p38 Activity and Inhibition 275
- 9.4 First-Generation Inhibitors 278
- 9.5 Pyridinyl-Imidazole Inhibitor: SB203580 278
- 9.6 N-Substituted Imidazole Inhibitors 282
- 9.7 N,N'-Diaryurea-Based Inhibitors: BIRB796 286
- 9.8 Structurally Diverse Clinical Candidates 288
- 9.9 Medicinal Chemistry Approach on VX-745-Like Compounds 297
- 9.10 Conclusion and Perspective for the Future 301
- References 302

10	Cellular Protein Kinases as Antiviral Targets	305
	<i>Luis M. Schang</i>	
10.1	Introduction	305
10.2	Antiviral Activities of the Pharmacological Cyclin-Dependent Kinase Inhibitors	310
10.2.1	Relevant Properties of CDKs and PCIs	310
10.2.2	Antiviral Activities of PCIs	327
10.2.2.1	Antiviral Activities of PCIs against Herpesviruses	327
10.2.2.2	Antiviral Activities of PCIs against HIV	332
10.2.2.3	Antiviral Activities of PCIs against Other Viruses	335
10.2.3	PCIs Can be Used in Combination Therapies	336
10.2.4	PCIs Inhibit Viral Pathogenesis	337
10.3	Antiviral Activities of Inhibitors of Other Cellular Protein Kinases	338
10.4	Conclusion	339
	References	341
11	Prospects for TB Therapeutics Targeting <i>Mycobacterium tuberculosis</i> Phosphosignaling Networks	349
	<i>Yossef Av-Gay and Tom Alber</i>	
11.1	Introduction	349
11.2	Rationale for Ser/Thr Protein Kinases and Protein Phosphatases as Drug Targets	350
11.3	Drug Target Validation by Genetic Inactivation	351
11.4	STPK Mechanisms, Substrates, and Functions	352
11.5	<i>M. tuberculosis</i> STPK Inhibitors	355
11.6	Conclusions and Prospects	359
	References	359
	Index	365